STOCK TITAN

Surgery Partners (NASDAQ: SGRY) director receives 11,670-share equity grant

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Surgery Partners, Inc. director Teresa DeLuca reported an acquisition of company common stock through an equity grant. On June 5, 2026, she received 11,670 shares of common stock at a reference price of $13.71 per share as a grant or award, not an open-market purchase. Following this grant, her directly held position increased to 56,843 shares of Surgery Partners common stock. According to a footnote, these granted shares are scheduled to vest on June 5, 2027, meaning they become fully earned over time rather than immediately.

Positive

  • None.

Negative

  • None.
Insider DeLuca Teresa
Role null
Type Security Shares Price Value
Grant/Award Common Stock 11,670 $13.71 $160K
Holdings After Transaction: Common Stock — 56,843 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Equity grant size 11,670 shares Common Stock grant on June 5, 2026
Grant reference price $13.71 per share Price per share for the reported grant
Total holdings after grant 56,843 shares Direct ownership following the transaction
Vesting date June 5, 2027 Date when granted shares vest
Transaction code A Grant, award, or other acquisition
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vest financial
"Shares will vest on June 5, 2027."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeLuca Teresa

(Last)(First)(Middle)
C/O SURGERY PARTNERS, INC.
340 SEVEN SPRINGS WAY, SUITE 600

(Street)
BRENTWOOD TENNESSEE 37027

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Surgery Partners, Inc. [ SGRY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A11,670(1)A$13.7156,843D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares will vest on June 5, 2027.
Remarks:
/s/ Jennifer Baldock, Attorney-in-Fact06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Teresa DeLuca report for SGRY?

Director Teresa DeLuca reported receiving 11,670 shares of Surgery Partners common stock as a grant or award on June 5, 2026. This is a compensation-related acquisition, not an open-market stock purchase or sale.

Was the SGRY insider transaction a stock purchase or a grant?

The transaction was a grant or award acquisition, coded "A" on Form 4. DeLuca did not buy these shares in the market; they were granted to her as part of her compensation, at a reference price of $13.71 per share.

How many SGRY shares does Teresa DeLuca hold after this Form 4 filing?

After the reported transaction, DeLuca directly holds 56,843 shares of Surgery Partners common stock. This total reflects her position following the grant of 11,670 shares reported on June 5, 2026 in the Form 4 filing.

When do the newly granted SGRY shares to Teresa DeLuca vest?

The footnote states that the 11,670 granted shares will vest on June 5, 2027. Vesting means the shares become fully earned and no longer subject to forfeiture conditions associated with the original equity award grant.

Does the SGRY Form 4 show any stock sales by Teresa DeLuca?

No stock sales are reported in this Form 4. The filing shows a single acquisition transaction via an equity grant of 11,670 common shares, with no corresponding dispositions, exercises, gifts, or tax-withholding entries listed.